A randomized, open label, comparative, multicentric study to assess the efficacy and safety of Fixed dose combination capsules of Celecoxib and Diacerein in comparison with Fixed dose combination tablets of Aceclofenac and Diacerein in patients suffering from osteoarthritis of knee and/or hip joints

Cadila Healthcare Ltd0 个研究点目标入组 200 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients of either sex of 18 to 60 years of age.
•2.Patients with an established diagnosis of osteoarthritis of knee and/or hip joints with at least moderate pain [at least 5 on the Visual Analogue Scale of 0 to 10 in Short Arthritis Assessment Scale (0 being no pain and 10 being severe pain)] at the affected site at the time of enrollment into the study.
•3.Informed consent of the patient/relative/legal representative.

•1.Pregnancy & lactation.
•2.Patients with hypersensitivity to Celecoxib, Aceclofenac, any other NSAIDs, Diacerein, anthraquinone derivatives or sulfonamides.
•3.Patients with hepatic and / or renal insufficiency.
•4.Patients with active peptic ulceration within the last 6 months.
•5.Patients suffering from coronary heart disease or any other significant cardiovascular disorder.
•6.Patients suffering from any hemorrhagic diasthesis.
•7.Patients with bronchial asthma, rhinitis, urticaria, or other allergic reactions induced by aspirin or other NSAIDs.
•8.Patients with any other serious concurrent illness or malignancy.
•9.Patients with continuing history of alcohol and / or drug abuse.
•10.Participation in another clinical trial in the past 3 months.

发起方